Biowaiver

In vivo bioavailability and/or bioequivalence investigations may be waived with a Biowaiver (not considered necessary for product approval). A dissolution test could be used as a surrogate basis for determining whether two medicinal items are equal instead of expensive and time-consuming in vivo trials. At the time, the Biowaiver was only used for pharmaceutical scale-up and post-approval adjustments (SUPAC).

  • High Solubility. High Permeability
  • Low solubility. High Permeability
  • High Solubility. Low Permeability
  • Low Solubility. Low Permeability

Related Conference of Biowaiver

November 26-27, 2024

3rd World Conference on Pharma Industry and Medical Devices

Zurich, Switzerland
November 26-27, 2024

3rd World Congress on Precision and Personalized Medicine

Zurich, Switzerland
November 28-29, 2024

39th World Congress on Pharmacology and Therapeutics

Paris, France
November 28-29, 2024

12th International Conference on Clinical Trials

Vancouver, Canada
December 05-06, 2024

17th World Drug Delivery Summit

Dubai, UAE
February 24-25, 2025

2nd International Conference on Pharmacognosy

Madrid, Spain
March 10-11, 2025

35th Annual European Pharma Congress

Rome, Italy
March 13-14, 2025

8th International on Pharmacy and Pharmaceutical Conference

Prague, Czech Republic
April 14-15, 2025

18th European Biosimilars Congress

Paris, France
June 16-17, 2025

3rd Global Online Summit on Nanoscience and Nanotechnology

Zurich, Switzerland
July 24-25, 2025

5th World Congress on Cardiovascular Medicine Pharmacology

Aix-en-Provence, France
September 23-24, 2025

10th International Conference on Future Pharma and Innovations

Amsterdam, Netherlands
October 22-23, 2025

7th European Conference on Advance Clinical Trials and Research

Aix-en-Provence, France

Biowaiver Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in